“… 42 , 43 The peptide GE11 was selected for EGFR targeting based on its convincingly demonstrated capacity to provide EGFR-specific transfection efficiency in nanoparticle delivery both in vitro and in vivo in our previous studies. 8 , 28 , 29 , 30 , 31 , 44 , 45 , 46 , 47 , 48 In the present study, we monitored vector biodistribution and transfection efficiency by non-invasive imaging in an orthotopic GBM mouse model and subsequently demonstrated the potential therapeutic efficacy of our novel GE11-targeted NIS polyplexes after 131 I application.…”